<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231878</url>
  </required_header>
  <id_info>
    <org_study_id>MT-2-01</org_study_id>
    <nct_id>NCT03231878</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.</brief_title>
  <acronym>Advance</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minoryx Therapeutics, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minoryx Therapeutics, S.L.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter, two
      parallel-group study in male patients with the AMN phenotype of X-linked adrenoleukodystrophy
      (X-ALD) to assess the efficacy and safety of MIN-102 treatment. Study sites will consist of
      specialist referral centers experienced in the management of adrenoleukodystrophy (ALD).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of MIN-102 on the progression of adrenomyeloneuropathy (AMN) in male patients as determined by a motor function test.</measure>
    <time_frame>in 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of MIN-102 in terms of patient reported outcomes.</measure>
    <time_frame>in 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SSPROM (Severity Score System for Progressive Myelopathy )</measure>
    <time_frame>in 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS (Expanded Disability Status Scale )</measure>
    <time_frame>in 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scales (Euroqol)</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Adrenoleukodystrophy</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIN-102</intervention_name>
    <description>MIN-102 treatment</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and between 18-65 years of age.

          -  Diagnosed with X-linked adrenoleukodystrophy (X-ALD) based on elevated VLCFA and
             genetic testing.

          -  Clinical evidence of spinal cord involvement.

        Exclusion Criteria:

          -  Any other chronic neurological disease with signs of spastic paraplegia, such as
             hereditary spastic paraplegia, multiple sclerosis, etc.

          -  Presence of inflammatory (Gd-enhancing) MRI lesions or any abnormality other than
             those mentioned in the inclusion criteria.

          -  Known type 1 or type 2 diabetes.

          -  Known intolerance to pioglitazone or any other thiazolidinedione.

          -  Taking or have taken honokiol, pioglitazone or other thiazolidinediones within the 6
             months prior to screening.

          -  Previous bone marrow transplantation.

          -  Previous or current history of cancer (other than treated basal cell carcinoma).

          -  Previous or current history of congestive heart failure.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Uwe Meya, MD</last_name>
    <phone>935441466</phone>
    <email>advance@minory.com</email>
  </overall_contact>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

